Catalent, Inc. (NYSE:CTLT) Sees Large Increase in Short Interest

Catalent, Inc. (NYSE:CTLT) was the target of a significant increase in short interest during the month of July. As of July 15th, there was short interest totalling 10,550,000 shares, an increase of 22.5% from the June 30th total of 8,610,000 shares. Based on an average daily trading volume, of 1,720,000 shares, the short-interest ratio is presently 6.1 days.

Catalent Stock Up 0.1 %

CTLT traded up $0.06 during trading hours on Tuesday, hitting $59.04. 2,095,975 shares of the company’s stock were exchanged, compared to its average volume of 2,204,608. The stock has a market cap of $10.69 billion, a price-to-earnings ratio of -9.68, a PEG ratio of 2.42 and a beta of 1.16. Catalent has a 1-year low of $31.80 and a 1-year high of $60.20. The stock’s 50-day moving average is $56.29 and its two-hundred day moving average is $55.84. The company has a quick ratio of 1.77, a current ratio of 2.51 and a debt-to-equity ratio of 1.37.

Catalent (NYSE:CTLT) last issued its quarterly earnings results on Wednesday, May 8th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of $0.21 by ($0.36). The business had revenue of $1.07 billion for the quarter, compared to the consensus estimate of $1.11 billion. Catalent had a negative return on equity of 2.73% and a negative net margin of 26.61%. Sell-side analysts predict that Catalent will post -0.17 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Ricky Hopson sold 1,401 shares of the stock in a transaction that occurred on Tuesday, June 4th. The shares were sold at an average price of $54.26, for a total value of $76,018.26. Following the transaction, the insider now directly owns 20,617 shares in the company, valued at $1,118,678.42. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other Catalent news, CEO Alessandro Maselli sold 9,088 shares of the stock in a transaction on Monday, July 29th. The shares were sold at an average price of $58.76, for a total value of $534,010.88. Following the sale, the chief executive officer now directly owns 177,521 shares in the company, valued at $10,431,133.96. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Ricky Hopson sold 1,401 shares of the business’s stock in a transaction on Tuesday, June 4th. The shares were sold at an average price of $54.26, for a total transaction of $76,018.26. Following the completion of the transaction, the insider now directly owns 20,617 shares of the company’s stock, valued at approximately $1,118,678.42. The disclosure for this sale can be found here. Insiders sold a total of 13,482 shares of company stock valued at $779,852 over the last ninety days. Insiders own 0.31% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of CTLT. Nisa Investment Advisors LLC lifted its stake in Catalent by 1.7% in the second quarter. Nisa Investment Advisors LLC now owns 11,013 shares of the company’s stock valued at $619,000 after acquiring an additional 185 shares during the last quarter. Lindbrook Capital LLC lifted its stake in Catalent by 79.4% in the 1st quarter. Lindbrook Capital LLC now owns 470 shares of the company’s stock valued at $27,000 after purchasing an additional 208 shares during the last quarter. GAMMA Investing LLC grew its holdings in Catalent by 25.9% during the second quarter. GAMMA Investing LLC now owns 1,032 shares of the company’s stock worth $58,000 after purchasing an additional 212 shares during the period. Czech National Bank increased its position in Catalent by 0.7% during the first quarter. Czech National Bank now owns 31,801 shares of the company’s stock worth $1,795,000 after buying an additional 228 shares during the last quarter. Finally, Sumitomo Mitsui DS Asset Management Company Ltd increased its position in Catalent by 1.4% during the second quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 19,238 shares of the company’s stock worth $1,082,000 after buying an additional 257 shares during the last quarter.

Analyst Ratings Changes

A number of research firms have issued reports on CTLT. StockNews.com assumed coverage on Catalent in a research note on Wednesday, July 24th. They issued a “sell” rating for the company. Stephens reiterated an “equal weight” rating and issued a $63.50 price objective on shares of Catalent in a research report on Thursday, April 4th. Royal Bank of Canada restated a “sector perform” rating and set a $63.50 target price on shares of Catalent in a report on Thursday, July 11th. Finally, Barclays upped their price target on shares of Catalent from $47.00 to $63.00 and gave the company an “equal weight” rating in a report on Friday, June 28th. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and three have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $55.65.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.